Leica Biosystems gains FDA clearance for AI quality-control software in cancer pathology

On August 11, 2026, Leica Biosystems announced FDA 510(k) clearances for a suite of digital pathology innovations designed to help laboratories accelerate cancer diagnosis while maintaining image quality. The centerpiece is Aperio iQC DX software, which the company describes as the industry's first standalone, AI-assisted quality control software cleared for clinical digital pathology. The software automatically detects six common image artifacts—air bubbles, pen marks, clipped tissue, missing tissue, out-of-focus regions, and image striping—while slides remain on the scanner, enabling laboratories to identify and fix quality issues before they create downstream delays.

Whole slide imaging has become standard in pathology, but the digitization process introduces new sources of error. Traditional histotechnician review catches some defects but misses others, leading to rescanning, rework, and diagnostic delays that accumulate when case volumes are high. Aperio iQC DX intercepts these problems earlier in the workflow. In a real-world data study conducted with the Institute of Pathology at Heidelberg University, the AI models detected up to 24% more artifacts missed by histotechnicians and reduced hands-on review time by 69%. This combination of better detection and faster processing helps laboratories move cases through the diagnostic pipeline without sacrificing quality, a critical advantage when staffing is tight and clinicians are waiting for results.

The clearances also expand Leica Biosystems' scanning hardware portfolio. The Aperio GT 180 DX scanner targets mid-volume laboratories seeking to scale digital pathology within their operational constraints; it offers a 180-slide capacity with the same scan speed and feature set as the company's higher-capacity Aperio GT 450 DX scanner. The GT 450 DX, which has a 450-slide capacity and industry-leading automation, received enhancements including new manual scan capabilities for complex slides, advanced DICOM capabilities, and z-stacking for the clinical environment. Together, these products give laboratories at different scales a way to build connected digital pathology workflows that support timely review and diagnostic confidence.

Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems, framed the announcements as part of a broader shift from standalone products to integrated clinical workflows. "Every improvement in the pathology workflow matters because patients and clinicians are waiting for answers that guide care," he said. "These FDA 510(k) clearances demonstrate Leica Biosystems' leadership in advancing digital pathology beyond individual products toward connected, standardized workflows that help laboratories operate with greater confidence and consistency." As a Danaher subsidiary, Leica Biosystems supports nearly 2 million cancer tests globally each week, giving it scale to refine AI models and integrate solutions across the full biopsy-to-diagnosis workflow, underscoring its position as a major player in the shift toward digital cancer diagnostics.